NASDAQ:FOLD Amicus Therapeutics Q3 2025 Earnings Report $8.10 -0.08 (-0.92%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Amicus Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.12Beat/MissN/AOne Year Ago EPSN/AAmicus Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$165.24 millionBeat/MissN/AYoY Revenue GrowthN/AAmicus Therapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Amicus Therapeutics Earnings HeadlinesZacks Research Brokers Boost Earnings Estimates for FOLDOctober 11 at 2:53 AM | americanbankingnews.comZacks Research Issues Positive Outlook for FOLD EarningsOctober 10, 2025 | americanbankingnews.comNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."October 14 at 2:00 AM | Goldco Precious Metals (Ad)A Look at Amicus Therapeutics’s Valuation After Analyst Upgrade and Improved Outlook (FOLD)October 6, 2025 | finance.yahoo.comNeedham Upgrades Amicus Therapeutics (FOLD)September 19, 2025 | msn.comAmicus upgraded to Buy at Needham banking on kidney disease therapySeptember 18, 2025 | msn.comSee More Amicus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amicus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amicus Therapeutics and other key companies, straight to your email. Email Address About Amicus TherapeuticsAmicus Therapeutics (NASDAQ:FOLD) (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function. The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants. Beyond Fabry disease, Amicus is advancing a pipeline of investigational gene therapies and combination therapies, including programs targeting Pompe disease and Batten disease, with several candidates in late‐stage and mid‐stage clinical development. Founded in 2005 and headquartered in Cranbury, New Jersey, Amicus Therapeutics completed its initial public offering on the NASDAQ in 2015. The company maintains research and development operations in multiple locations across the United States and Europe, leveraging global manufacturing and regulatory expertise to support its clinical trials and commercial supply chain. Leadership at Amicus includes Chief Executive Officer Chirfi Guindo, who brings extensive experience in rare disease drug development, and John Crowley, co‐founder and Chairman of the Board. The company collaborates with leading pharmaceutical and academic partners to expand its platform and accelerate the development of novel therapies for underserved patient communities.View Amicus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025)Kinder Morgan (10/15/2025)Morgan Stanley (10/15/2025)Progressive (10/15/2025)Prologis (10/15/2025)The PNC Financial Services Group (10/15/2025)CSX (10/16/2025)Interactive Brokers Group (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
